Dr Lee on the Significance of Longer-Term Data for Linvoseltamab in R/R Multiple Myeloma

Commentary
Video

In Partnership With:

Hans C. Lee, MD, discusses the significance of longer-term data for linvoseltamab from the LINKER-MM1 study in relapsed/refractory multiple myeloma.

Hans C. Lee, MD, associate professor, Department of Lymphoma/Myeloma, Multiple Myeloma Clinical Research, Department of Lymphoma/Myeloma, Division of Cancer Medicine, the University of Texas MD Anderson Cancer Center, discusses how longer-term efficacy and safety data with linvoseltamab (REGN5458) derived from the phase 2 LINKER-MM1 study (NCT03761108) may potentially impact treatment approaches in relapsed/refractory multiple myeloma.

The study investigated linvoseltamab, a BCMA/CD3-directed bispecific antibody, in a heavily pretreated patient population with relapsed/refractory multiple myeloma which demonstrated promising results in terms of efficacy and safety. The dose escalation/expansion study enrolled patients who had progressed on multiple lines of therapy, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody, or who were triple-class refractory.

Patients enrolled onto the dose-expansion portion of the study underwent step-up dosing with linvoseltamab, followed by a 24-hour hospitalization period, Lee details. The weekly step-up dosing regimen, starting with 5 mg on day 1 and 25 mg on day 8, differentiated linvoseltamab from other treatments. During the initial 3 treatment cycles, patients were administered 200 mg of linvoseltamab once weekly. Subsequently, in cycles 4 and 5, the dosage was modified to 200 mg every 2 weeks. Starting from cycle 6, patients achieving a very good partial response (VGPR) or higher received the agent at a dosage of 200 mg every 4 weeks. Those who did not achieve a VGPR continued to receive the agent at a dosage of 200 mg every 2 weeks. This weekly step-up dosing regimen was a notable distinguishing feature of linvoseltamab, Lee notes.

Long-term data from the study presented at the 2023 ASH Annual Meeting, showed high response rates with linvoseltamab, with an overall response rate (ORR) of 69% at a median follow-up of 8.1 months, Lee reports. Furthermore, the median duration of response and progression-free survival (PFS) were not reached, with estimated 9-month rates of 86.8% and 72.8%, respectively. Importantly, linvoseltamab exhibited a generally manageable toxicity profile with no new safety signals identified.

Additional data from the LINKER-MM1 study, published later in 2023, demonstrated even higher ORR of 71% as adjudicated by an independent review committee and a complete response rate of 46% at an 11-month median follow-up, Lee reports. These findings suggest that linvoseltamab shows continued efficacy, durability of responses, and encouraging safety signals in relapsed/refractory multiple myeloma, Lee explains.

The rapid de-escalation of dosing frequency, limited hospitalization requirements for cytokine release syndrome (CRS) monitoring, and low CRS rates make linvoseltamab a promising approach for the treatment of patients with relapsed/refractory multiple myeloma, Lee concludes.

Related Videos
Petros Grivas, MD, PhD, professor, Clinical Research Division, Fred Hutchinson Cancer Center; professor, Division of Hematology and Oncology, University of Washington (UW) School of Medicine; clinical director, Genitourinary Cancers Program, UW Medicine
Somedeb Ball, MBBS, assistant professor, medicine, Division of Hematology Oncology, Department of Medicine, Vanderbilt University Medical Center
Phillip J. Koo, MD
Gabriella Smith, MD
Mikkael A. Sekeres, MD, MS
Francesco Di Meo, PhD
Ko Un “Clara” Park, MD
Naseema Gangat, MBBS
Erin Frances Cobain, MD
Pashtoon Murtaza Kasi, MD, MS